KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) EBT Margin (2018 - 2025)

Historic EBT Margin for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to 67905.42%.

  • Vir Biotechnology's EBT Margin fell 589331500.0% to 67905.42% in Q3 2025 from the same period last year, while for Sep 2025 it was 2961.95%, marking a year-over-year decrease of 22761200.0%. This contributed to the annual value of 704.95% for FY2024, which is 239900.0% up from last year.
  • Latest data reveals that Vir Biotechnology reported EBT Margin of 67905.42% as of Q3 2025, which was down 589331500.0% from 9125.86% recorded in Q2 2025.
  • Over the past 5 years, Vir Biotechnology's EBT Margin peaked at 106.9% during Q3 2021, and registered a low of 67905.42% during Q3 2025.
  • Over the past 5 years, Vir Biotechnology's median EBT Margin value was 719.35% (recorded in 2023), while the average stood at 6160.27%.
  • Its EBT Margin has fluctuated over the past 5 years, first skyrocketed by 86130100bps in 2022, then plummeted by -589331500bps in 2025.
  • Vir Biotechnology's EBT Margin (Quarter) stood at 67.17% in 2021, then tumbled by -557bps to 306.9% in 2022, then tumbled by -134bps to 719.35% in 2023, then decreased by -18bps to 845.93% in 2024, then crashed by -7927bps to 67905.42% in 2025.
  • Its EBT Margin was 67905.42% in Q3 2025, compared to 9125.86% in Q2 2025 and 3989.08% in Q1 2025.